Clinical Trials Browser

Recruiting × Interventional × peposertib × Clear all

NCT04071236 2026-03-18

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04172532 2026-03-18

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05687136 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT04555577 2025-10-29

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Phase 1 Recruiting

Glioblastoma, Gliosarcoma

NCT05868174 2024-05-01

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Phase 1 Recruiting

GenitourinaryOther solid neoplasm

Solid Tumor, Adult